Business Context and Reporting Period
This Form 6-K filing by GSK plc, dated June 2, 2025, reports a significant regulatory milestone for its investigational drug, linerixibat. The filing announces that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for linerixibat for the treatment of cholestatic pruritus (relentless itch) in patients with primary biliary cholangitis (PBC).
Key Financial Metrics
The filing text does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on clinical development and regulatory status.
Material Changes and Developments
- Regulatory Acceptance: The FDA accepted the NDA for linerixibat, an ileal bile acid transporter (IBAT) inhibitor.
- Decision Timeline: The Prescription Drug User Fee Act (PDUFA) goal date for the FDA decision is set for March 24, 2026.
- Clinical Basis: The application is supported by positive data from the GLISTEN Phase III trial, which met both primary and key secondary endpoints regarding itch reduction and sleep interference versus placebo.
- Global Status: Linerixibat is currently not approved anywhere in the world but holds orphan drug designation in both the U.S. and Europe.
Outlook, Risks, and Management Commentary
Management, represented by Kaivan Khavandi (SVP, Global Head, Respiratory, Immunology & Inflammation R&D), views this acceptance as a critical milestone. They emphasize the potential for linerixibat to address a high unmet medical need, as current first-line treatments for PBC do not adequately reduce pruritus severity. The drug targets the mechanism of bile acid re-uptake to reduce mediators of pruritus.
Risks and Contingencies: The filing includes a standard cautionary statement regarding forward-looking statements. Actual results may differ materially due to risks described in GSK's 2024 Form 20-F and Q1 2025 results. There is no guarantee of FDA approval by the PDUFA date.
Key Facts for Investor Verification
- Verify the PDUFA decision date of March 24, 2026, for the linerixibat NDA.
- Review the full GLISTEN Phase III trial data presented at the EASL Congress in May 2025 to assess the magnitude of efficacy and safety profile.
- Monitor the FDA's review process for any requests for additional information that could delay the decision.
- Assess the potential market size for cholestatic pruritus in PBC patients, noting that up to 90% of PBC patients experience this symptom.
- Check GSK's broader hepatology pipeline, which includes investigations into chronic hepatitis B, alcohol-related liver disease, and MASH.